Ameritas Investment Partners’s Theravance Biopharma TBPH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $62.3K | Buy |
3,662
+588
| +19% | +$9.73K | ﹤0.01% | 2129 |
|
|
2026
Q1 | $49.9K | Hold |
3,074
| – | – | ﹤0.01% | 2094 |
|
|
2025
Q4 | $57.5K | Sell |
3,074
-524
| -15% | -$8.69K | ﹤0.01% | 2028 |
|
|
2025
Q3 | $52.5K | Hold |
3,598
| – | – | ﹤0.01% | 2084 |
|
|
2025
Q2 | $39.7K | Hold |
3,598
| – | – | ﹤0.01% | 2334 |
|
|
2025
Q1 | $32.1K | Hold |
3,598
| – | – | ﹤0.01% | 2344 |
|
|
2024
Q4 | $33.9K | Hold |
3,598
| – | – | ﹤0.01% | 2405 |
|
|
2024
Q3 | $29K | Hold |
3,598
| – | – | ﹤0.01% | 2474 |
|
|
2024
Q2 | $30.5K | Sell |
3,598
-2,485
| -41% | -$22.4K | ﹤0.01% | 2414 |
|
|
2024
Q1 | $54.6K | Hold |
6,083
| – | – | ﹤0.01% | 2098 |
|
|
2023
Q4 | $68.4K | Hold |
6,083
| – | – | ﹤0.01% | 1975 |
|
|
2023
Q3 | $52.5K | Buy |
6,083
+1,446
| +31% | +$14K | ﹤0.01% | 2078 |
|
|
2023
Q2 | $48K | Hold |
4,637
| – | – | ﹤0.01% | 2077 |
|
|
2023
Q1 | $50.3K | Hold |
4,637
| – | – | ﹤0.01% | 1977 |
|
|
2022
Q4 | $50.5K | Hold |
4,637
| – | – | ﹤0.01% | 2044 |
|
|
2022
Q3 | $47K | Hold |
4,637
| – | – | ﹤0.01% | 2031 |
|
|
2022
Q2 | $42K | Hold |
4,637
| – | – | ﹤0.01% | 2107 |
|
|
2022
Q1 | $44K | Hold |
4,637
| – | – | ﹤0.01% | 2133 |
|
|
2021
Q4 | $51K | Buy |
4,637
+843
| +22% | +$7.35K | ﹤0.01% | 2120 |
|
|
2021
Q3 | $28K | Hold |
3,794
| – | – | ﹤0.01% | 2516 |
|
|
2021
Q2 | $55K | Hold |
3,794
| – | – | ﹤0.01% | 2117 |
|
|
2021
Q1 | $77K | Sell |
3,794
-488
| -11% | -$9.28K | ﹤0.01% | 1813 |
|
|
2020
Q4 | $76K | Hold |
4,282
| – | – | ﹤0.01% | 1723 |
|
|
2020
Q3 | $63K | Hold |
4,282
| – | – | ﹤0.01% | 1698 |
|
|
2020
Q2 | $90K | Buy |
4,282
+310
| +8% | +$7.96K | ﹤0.01% | 1480 |
|
|
2020
Q1 | $92K | Buy |
3,972
+306
| +8% | +$7.66K | 0.01% | 1320 |
|
|
2019
Q4 | $95K | Hold |
3,666
| – | – | ﹤0.01% | 1547 |
|
|
2019
Q3 | $71K | Hold |
3,666
| – | – | ﹤0.01% | 1671 |
|
|
2019
Q2 | $60K | Hold |
3,666
| – | – | ﹤0.01% | 1820 |
|
|
2019
Q1 | $83K | Hold |
3,666
| – | – | ﹤0.01% | 1588 |
|
|
2018
Q4 | $94K | Hold |
3,666
| – | – | 0.01% | 1427 |
|
|
2018
Q3 | $120K | Hold |
3,666
| – | – | 0.01% | 1430 |
|
|
2018
Q2 | $83K | Hold |
3,666
| – | – | ﹤0.01% | 1656 |
|
|
2018
Q1 | $89K | Sell |
3,666
-199
| -5% | -$5.46K | ﹤0.01% | 1564 |
|
|
2017
Q4 | $150K | Hold |
3,865
| – | – | 0.01% | 1257 |
|
|
2017
Q3 | $125K | Hold |
3,865
| – | – | 0.01% | 1323 |
|
|
2017
Q2 | $153K | Buy |
3,865
+230
| +6% | +$8.84K | 0.01% | 1200 |
|
|
2017
Q1 | $133K | Buy |
3,635
+3,407
| +1,494% | +$109K | 0.01% | 1269 |
|
|
2016
Q4 | $7K | Hold |
228
| – | – | ﹤0.01% | 1211 |
|
|
2016
Q3 | $8K | Hold |
228
| – | – | ﹤0.01% | 1201 |
|
|
2016
Q2 | $5K | Hold |
228
| – | – | ﹤0.01% | 1147 |
|
|
2016
Q1 | $4K | Hold |
228
| – | – | ﹤0.01% | 1163 |
|
|
2015
Q4 | $3K | Buy |
+228
| New | +$3.62K | ﹤0.01% | 1164 |
|
Other funds holding TBPH
MAP
WAM
NM
ICM
Ameritas Investment Partners's TBPH Position: Q2 2026 in Review
Ameritas Investment Partners increased its Theravance Biopharma (TBPH) stake by 19% in Q2 2026, buying an estimated $9.73K and bringing the position to 3,662 shares worth $62.3K. The position accounts for ﹤0.01% of the portfolio, ranked #2129.
Ameritas Investment Partners first reported a position in TBPH in Q4 2015 and has held it in 43 quarters since. The position peaked at $153K in Q2 2017. 180 funds tracked by Wall St. Rank hold TBPH as of Q2 2026.
- Ameritas Investment Partners held 3,662 shares of Theravance Biopharma worth $62.3K as of Q2 2026.
- Ameritas Investment Partners bought 588 Theravance Biopharma shares in Q2 2026, an estimated $9.73K.
- Theravance Biopharma made up ﹤0.01% of Ameritas Investment Partners's portfolio in Q2 2026, its #2129 holding.
- Ameritas Investment Partners first reported a position in Theravance Biopharma in Q4 2015 and has held it in 43 quarters since.
- Ameritas Investment Partners's Theravance Biopharma position peaked at $153K in Q2 2017.
- 180 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2026.
Based on Ameritas Investment Partners's 13F filing for Q2 2026, filed 13 Aug 2026.